Ovarian Cancer Trial, Recruiting NCT06050109 Sponsor: Hongmei Zheng, PhD Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06050109
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with early-stage primary breast cancer
  • Women between the ages of 18 and 60 years old (including those aged exactly 18 or 60)
  • People whose breast cancer is hormone receptor (HR) positive and HER2 negative (these are specific characteristics of the cancer cells, confirmed by testing)
  • People who have received 5 years of ovarian function suppression (OFS) treatment, which is a therapy that reduces the hormones produced by the ovaries
  • People with an ECOG performance score of 0 or 1, meaning they are either fully active or have only minor restrictions in physical activity (confirm with trial site)
  • People who are willing to participate voluntarily and sign a consent form
  • People whose treating doctor believes they may benefit from joining the trial

Who may not be able to join:

  • People who are currently receiving other treatments that interfere with ovarian function suppression (OFS) therapy, or who have received OFS treatment for less than 5 years
  • People with known and clearly symptomatic cancer spread to the brain or central nervous system, such as headaches, brain swelling, or blurred vision
  • People with known and clearly symptomatic cancer that has spread to other parts of the body (invasive metastases) (confirm with trial site for full details)
  • People whose treating doctor considers the trial to be unsuitable for them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hongmei Zheng, Doctor, Study Principal Investigator

Phone: 18971624606

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hongmei Zheng, PhD
Registry
ClinicalTrials.gov
Start date
1 September 2023
Est. completion
1 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

invasive disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov